DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Clinical trial NCT02166905 · COMPLETED
Trial details
- NCT number
- NCT02166905
- Sponsor
- Roswell Park Cancer Institute
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-10
- Primary completion
- 2020-08-20
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.